Moderator
Alan P. Venook, MD 
Professor of Clinical Medicine and Associate Chief
Division of Medical Oncology
University of California, San Francisco
Comprehensive Cancer Center
San Francisco, California  

Presented By
Cathy Eng, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas 

Peter J. O'Dwyer, MD
Professor of Medicine
Director, Developmental Therapeutics Program,
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania 

Activity Description
Colorectal cancer represents the third most frequently diagnosed cancer in the US with 148,610 new cases expected in 2006. Colorectal cancer is also the second leading cause of death due to cancer among males and the third leading cause among females with a total of 55,170 deaths expected from the disease in 2006. Incidence and death rates have been declining in the past 2 decades in part due to increased screening, polyp removal, and better therapies. While few new regimens for metastatic colorectal cancer have been introduced recently, there have been advances in the optimization of existing regimens that could ultimately impact patient outcomes. While the optimal sequencing of these agents continues to be studied, the addition of biologic agents has also shown some added benefit. This educational activity is designed to improve the understanding of metastatic colorectal cancer, as well as to provide an understanding of novel agents, their use in current clinical trials, and the optimization of currently available treatment options.

Intended Audience 
This activity has been designed to meet the educational needs of health care professionals such as physicians, nurses, and pharmacists involved in the care of patients with metastatic colorectal cancer.

Learning Objectives

1. Review the biology and pathophysiology of colorectal cancer to better understand the rationale and appropriateness of metastatic treatment
2. Discuss current approaches, as well as treatment goals, for patients with metastatic colorectal cancer
3. Define the rationale for use of newer biologics with current treatment strategies
4. Demonstrate an understanding of the data supporting new and investigational approaches for treatment of metastatic colorectal cancer patients

Accreditation Statements/Credit Designation:
i3 CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

i3 CME designates this educational activity for a maximum of 1 AMA PRA Ca